Allopurinol: indications and tactics of prescription
- Authors: Lebedeva MV1
-
Affiliations:
- Issue: No 1 (2009)
- Pages: 77-79
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245866
- ID: 245866
Cite item
Full Text
Abstract
Indications and contraindications for allopurinol use are discussed
Keywords
References
- Мухин Н.А., Балкаров И.М. Подагрическая почка. В: Тареева И.Е. (ред.) Нефрология: руководство для врачей. М., 2000. С. 422-28.
- Yamamoto T, Moriwaki Y, Takahashi S, et al. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol and purine bases between dietary intake and fasting. Int J Clin Pharmacol Ther 1996;34(4):157-62.
- Locatelli F, Rossi P. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 2005;147:61-68.
- Marangella M. Uric acid elimination in the urine. Contrib Nephrol 2005;147:132-18.
- Lee HY, Pang SM, Thamotharampillai T. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 2008;59(2):352-53.
- Tausche AK, Aringer M, Schroeder HE, et al. The Janus faces of allopurinol-allopurinol hypersensitivity syndrome. Am J Med 2008;121(3):e3-e4.
- Halpern R, Fuldeore MJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009;15(1):3-7.
- Chung Y, Lu CY, Graham GG, et al. Utilization of allopurinol in the Australian community. Intern Med J 2008;38(6):388-95.
- Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008;31(8):643-65.
- Мухин Н.А., Шоничев Д.Г., Балкаров И.М. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек //Терапевтический архив. 1999. № 6. С. 12-24.
- Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300(8):924-32.
- Richard J, Johnson MD, Salah D, et al. Reappraisal of pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease and renal disease. Am J Kidney Dis 1999;33:225-34.
- Farquharson CAJ, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-26.
- George J, Struthers AD. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther 2008;26(1):59-64.
- Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004;71(6):481-85.
- Cammalleri L, Malaguarnera M. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. Int J Med Sci 2007;4(2):83-93.
- Pui CH. Rasburicase: a potent uricolytic agent. Exp Opin Pharm 2002;3:433-42.
Supplementary files
